BlueCrest Capital Management’s Teva Pharmaceuticals TEVA Stock Holding History

BlueCrest Capital Management’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-148,084	Closed	-$4.75M	–	1099
2017 Q1	$4.75M	Buy	+148,084	New	+$5.05M	0.22%	128
2016 Q4	–	Sell	-25,000	Closed	-$998K	–	870
2016 Q3	$1.15M	Buy	+25,000	New	+$1.3M	0.04%	365
2016 Q2	–	Sell	-11,401	Closed	-$610K	–	1039
2016 Q1	$610K	Buy	+11,401	New	+$669K	0.04%	466

Other funds holding TEVA

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $30.5B AUM 29.95% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

HCM

Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Northern Cross Boston, Massachusetts $279M AUM 1.98% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

BlueCrest Capital Management's TEVA Position: Q2 2017 in Review

BlueCrest Capital Management sold out of Teva Pharmaceuticals (TEVA) in Q2 2017, closing a stake of 148,084 shares — an estimated $4.75M sold.

BlueCrest Capital Management first reported a position in TEVA in Q1 2016 and held it in 3 quarters. The position peaked at $4.75M in Q1 2017. 648 funds tracked by Wall St. Rank hold TEVA as of Q2 2017.

BlueCrest Capital Management reported no remaining Teva Pharmaceuticals position as of Q2 2017 after selling out during the quarter.
BlueCrest Capital Management sold 148,084 Teva Pharmaceuticals shares in Q2 2017, an estimated $4.75M.
BlueCrest Capital Management first reported a position in Teva Pharmaceuticals in Q1 2016 and held it in 3 quarters.
BlueCrest Capital Management's Teva Pharmaceuticals position peaked at $4.75M in Q1 2017.
648 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2017.

Based on BlueCrest Capital Management's 13F filing for Q2 2017, filed 14 Aug 2017.